Cargando…

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

BACKGROUND: Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with sustained efficacy during maintenance treatment. As part of a phase 3 randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2015
Materias:	Original Article—Alimentary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766223/ https://www.ncbi.nlm.nih.gov/pubmed/26162647 http://dx.doi.org/10.1007/s00535-015-1102-z

Ejemplares similares

Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2020)

Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
por: Naganuma, Makoto, et al.
Publicado: (2017)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2021)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
por: Hibi, Toshifumi, et al.
Publicado: (2017)

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
por: Kobayashi, Taku, et al.
Publicado: (2017)

Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease
por: Umeno, Junji, et al.
Publicado: (2018)

Impact of inflammatory bowel disease on Japanese patients’ quality of life: results of a patient questionnaire survey
por: Ueno, Fumiaki, et al.
Publicado: (2016)

Selective expansion of intraepithelial lymphocytes expressing the HLA-E–specific natural killer receptor CD94 in celiac disease()()
por: Jabri*, ‡, §, Bana, et al.
Publicado: (2000)

Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases
por: Zhang, Hu, et al.
Publicado: (2020)

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey
por: Marasco, Giovanni, et al.
Publicado: (2020)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
por: Bossa, Fabrizio, et al.
Publicado: (2021)

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
por: Maconi, Giovanni, et al.
Publicado: (2021)

Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study
por: Ianiro, Gianluca, et al.
Publicado: (2020)

Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area
por: Elli, Luca, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
por: Arrigo, Serena, et al.
Publicado: (2021)

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
por: Viazis, N., et al.
Publicado: (2023)

Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case–control study
por: Esaki, Motohiro, et al.
Publicado: (2018)

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study
por: Shinzaki, Shinichiro, et al.
Publicado: (2021)

Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite–Canada syndrome: a Japanese nationwide survey
por: Watanabe, Chikako, et al.
Publicado: (2015)

Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)
por: Nakase, Hiroshi, et al.
Publicado: (2022)

A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan
por: Ando, Katsuyoshi, et al.
Publicado: (2021)

Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey
por: Nakase, Hiroshi, et al.
Publicado: (2023)

Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis
por: Bakke, Ingunn, et al.
Publicado: (2021)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Food antigen-induced immune responses in Crohn’s disease patients and experimental colitis mice
por: Kawaguchi, Takaaki, et al.
Publicado: (2014)

Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
por: Parkes, Gareth, et al.
Publicado: (2023)

Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan
por: Yasukawa, Shigeyoshi, et al.
Publicado: (2018)

Mucin Gene Deficiency in Mice Impairs Host Resistance to an Enteric Parasitic Infection
por: Hasnain, Sumaira Z., et al.
Publicado: (2010)

IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease
por: Tremelling, Mark, et al.
Publicado: (2007)

Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup Mutations
por: Camargo, Simone M.R., et al.
Publicado: (2009)

The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
por: Yamawaka, Tsukasa, et al.
Publicado: (2022)

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
por: Kakuta, Yoichi, et al.
Publicado: (2018)

Endoscopic evaluation by the Kyoto classification of gastritis combined with serum anti-Helicobacter pylori antibody testing reliably risk-stratifies subjects in a population-based gastric cancer screening program
por: Hirai, Ryosuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3rtdseepgofcrgbdcavslf3eki